Theratechnologies Inc T.TH

JonesTrading initiates Buy & sets $6 price target

[PWIB123]

Never heard of JonesTrading or the analyst Justin Walsh, but I'll take any positive news we can get.

[SPCEO1]

I have had a quick look at the report and it seems well done. It  is 36 pages long. He gives no value to NASH yet (Cantor gave it significant value) and more value to TH-1902 and the SORT1+ platform (he has some royalty payments factored in as well as direct revenues from it starting in 2026). Jones is a retail oriented broker.  So, for those of us who have been asking for something on

[mikeq113]

It's starting to feel like the stage is being set for some important news. Hopefully we get tangible updates soon...

[PWIB123]

This is good news!  We lost another 2 followers on StockTwits this week after losing several last week.  Today is a heavy trading day with a pop early this morning and yet we are at nil.  Someone is still selling when they can.  Hopefully we will see more retail investors begin to invest and start to push the price up.

[Wino115]

Very helpful step in starting to build the investment environment that could support a solid case if positive developments come from Phase 1 trial.  It's putting in place a few steps to rectify a glaring weakness - solid oncology analysts talking about the potential for SORT1 and TH1902 being a game-changer.  Only fair to applaud those who got it there -CEO, CFO and IR - so job

[JohnBelg]

https://www.jonestrading.com/services/research/ Justin Walsh PhD covers biotechnology companies within the Healthcare sector. Before joining JonesTrading, Dr. Walsh was a Research Analyst at B. Riley Securities covering SMID cap biotechnology and healthcare companies with a primary focus on oncology. Earlier, he contributed to the coverage of a diverse set of biotechnology companies as an equity